Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 6/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GABRP | O00591 | 1/20 | 0.46 |
| ▸ | GABRD | O14764 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5952424 | 0.89 | MMP13 (0.47) | SMN1; SMN2MMP13ROCK2 | |
| SCHEMBL5953304 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2KDM4EMAPTKMT2A | |
| SCHEMBL5952675 | 0.86 | PDPK1 (0.47) | SMN1; SMN2MAPTLMNA | |
| SCHEMBL5952503 | 0.86 | KMT2A (0.52) | SMN1; SMN2MAPTAPEX1LMNAGABRP | |
| SCHEMBL5951853 | 0.86 | SMN1; SMN2 (0.48) | SMN1; SMN2HPGDALDH1A1MMP13LMNA | |
| SCHEMBL5953264 | 0.85 | FGFR1 (0.46) | SMN1; SMN2MAPTROCK2 | |
| SCHEMBL5951941 | 0.84 | PDPK1 (0.50) | SMN1; SMN2HPGDLMNA | |
| SCHEMBL5952802 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2USP2ALDH1A1MMP13ROCK2 | |
| SCHEMBL13373609 | 0.83 | USP2 (0.49) | SMN1; SMN2HPGDKDM4EUSP2ALDH1A1 | |
| SCHEMBL5951852 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | claimed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | SMN1; SMN2 4210/4885HPGD 1307/4885KDM4E 522/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | SMN1; SMN2 3516/4885HPGD 1623/4885KDM4E 645/4885 |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | KDR, MUSK, FLT4 | SMN1; SMN2 1094/4885HPGD 3957/4885KDM4E 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.